ACET
Adicet Bio, Inc. Common Stock
stockNASDAQ
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet's gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.53 | 2026-10-19 | -11.23% | 3.216 |
| 1M | 9.02 | 2026-09-25 | -55.42% | 5.319 |
| 3M | 7.79 | 2026-07-24 | -48.38% | 2.206 |
| 6M | 7.90 | 2026-04-24 | -49.10% | 2.062 |
| 1Y | 14.24 | 2025-10-24 | -71.76% | 2.153 |
| 2Y | 22.40 | 2024-10-25 | -82.05% | — |
| 5Y | 126.08 | 2021-10-25 | -96.81% | 1.363 |
Adicet Bio, Inc. Common Stock (NASDAQ:ACET) stock price today is $4.02, and today's volume is 162,967. ACET is down 6.042% today. The 30 day average volume is 302,057. ACET market cap is $37.65M with 9.36M shares outstanding.